As COVID-19 spreads across the globe, new research funding opportunities are cropping up, along with questions regarding how COVID-19-related disruptions to research might affect current federal funding. Answers to many of those questions and information on a variety of new funding opportunities is provided by clicking on the related link below:

1. New Covid-19 research funding opportunities
2. COVID-19 related research news and policy updates
3. Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19
4. Free access and free services for researchers related to COVID-19
5. COVID-19 news by Chan faculty

**Internal COVID-19 Funding Announcements**

**Non-federal COVID-19 Funding Announcements**

*NEW: Greenwall Foundation: Making a Difference in Real World Bioethics Dilemmas*
Deadline: June 24, 2020
The bioethics grants program support research to help resolve an important emerging or unanswered bioethics problem in clinical, biomedical, or public health decision-making, policy, or practice. The Foundation’s vision is to make bioethics integral to decisions in health care, policy, and research. Our mission is to expand bioethics knowledge to improve clinical, biomedical, and public health decision-making, policy, and practice. Projects funded under the Making a Difference program should promote the Foundation’s vision and mission through innovative bioethics research that will have a real-world, practical impact.

*NEW: WorkRise: From COVID-19 Response to Equitable Recovery*
Deadline: June 29, 2020
Hosted by the Urban Institute, WorkRise is launching a drive to rapidly develop and share actionable evidence about what works to shore up workers’ economic security in the short-term and promote upward mobility in the medium- and longer-term. To achieve these objectives, WorkRise is issuing both a Request for Proposals (RFP) and a Request for Information (RFI) to identify and accelerate innovative solutions—including programs, policies, and practices—that not only provide immediate economic relief to struggling workers and those who are out of work, but also create pathways for greater economic security and upward mobility in the long term. The RFP is designed for those with research projects in
need of funding, while the RFI is designed for those who have identified promising, scalable practices in need of additional support and/or research and evaluation.

*NEW: CISCO: Pandemic/COVID19 Science, Technology and Social Impact
Deadline: Continuous
This program seeks applications that solve problems ranging from predictive analytics innovative devices for saving lives to technology for devising voting machines. Areas of interest include, but are not limited to: Mathematical models for spread and the impact of pandemics; Scalable simulation techniques for pandemics (e.g. with multi agents); Biomedical/Nano sensor devices for detecting symptoms and agents; Algorithms for rapid exploration of the drug screening and discovery workflows (e.g. use reinforcement learning); Advanced computational biology techniques for sequencing, detecting viral evolution (e.g. in COVID-19); Algorithms and systems for contact tracing (with privacy preserving); Algorithms and recommendation systems for curating media and news; Collaboration techniques for more effective health, and efficiency during pandemics; Improved identity and security techniques; Distributed Ledgers, their applications and their governance for and during pandemics; Pandemic data science; Understanding the patterns and the impact of a pandemic like COVID-10; and Creation of curated data sets

United Nations Industrial Development Organization: Innovative Ideas and Technologies vs. COVID-19 and Beyond
Deadline: June 30, 2020
The Innovative Ideas and Technologies vs. COVID-19 and Beyond call for proposals is aimed at identifying scalable solutions to cope with the direct and indirect impact of COVID-19 in developing countries and economies in transition, and their respective needs in the transition to post-crisis socioeconomic realities in the aftermath of the pandemic. Priority is given to the following categories: Health Emergency, Energy and Environment, Food and Agriculture, and Resilient Industries and Infrastructure.

The Gordon and Betty Moore Foundation: Diagnostic Excellence Initiative
Deadline: June 30, 2020
This funding opportunity solicits novel ideas and approaches for developing new clinical quality measures to improve diagnosis, specifically targeting three major categories of disease: acute vascular events (such as stroke and myocardial infarction), infections (such as sepsis and pneumonia) and cancer (such as lung and colorectal).

Society for Medical Decision Making: COVID-19 Decision Modeling Grant
Deadline: June 30, 2020
The COVID Decision Modeling Initiative (CDMI) will support the development of decision models to inform the urgent needs of decision makers responding to the Covid-19 pandemic. CDMI has several specific goals to facilitate responsive decision modeling research: Determine key priorities and critical questions where decision modeling can support better decisions and outcomes during the COVID-19 pandemic; Implement grant making program to fund 6-10 projects with rapid impact potential; and Leverage Society for Medical Decision Making (SMDM) repository of models and network of decision modelers addressing COVID-19

International Development Research Centre: COVID-19 Global South Artificial Intelligence and Data Innovation Program
Deadline: June 28, 2020
The International Development Research Centre (IDRC) and the Swedish International Development Cooperation Agency are contributing up to CA$10 million towards a COVID-19 Global South Artificial
Intelligence and Data Innovation Program. The Program aims to support multidisciplinary research to deepen understanding of how to develop and scale responsible (inclusive, rights-based, ethical, and sustainable) evidence-based artificial intelligence and data science approaches that support COVID-19 response and recovery in low- and middle-income countries.

Department for International Development: Building Resilient Health Systems through the COVID-19 Pandemic and Beyond
Deadline: June 18, 2020
This Call explores the role of technology and innovations in supporting countries (Africa and Asia) and their development partners to build resilient health systems as they respond to the COVID-19 crisis. This call aims to focus attention and build community around an important part of the pandemic response: the maintenance of essential health services (RMNCAH, non-communicable diseases, nutrition, malaria, HIV/AIDS, tuberculosis, etc.).

Pfizer: Vaccine Preventable Diseases-COVID-19
Deadline: June 17, 2020
This RFP supports research to increase knowledge of COVID-19 epidemiology, infection, pathophysiology and potential prevention measures. We are particularly interested in supporting research in the following areas: Understand impact of COVID on communities, spectrum of disease in communities, and level of herd immunity; Postmortem Analysis of deceased persons with known or suspected COVID-19.

UK Robotics: Medical Robotics for Contagious Diseases Challenge
Deadline: September 30, 2020
The COVID-19 pandemic offers a unique opportunity to galvanize medical robot technologies, as they play an increasingly major role in combating contagious diseases. This new international challenge is aimed at entries that could offer solutions as part of a multi-faceted response to this and future global pandemics.

Social Science Research Council (SSRC): The Social Data Research Fellowship
Deadline: June 16, 2020
These fellowships seek to encourage multifaceted pathways for the collection and analysis of social data, with the larger aim of cultivating robust research on technology and society. In particular, we are interested in supporting research that makes creative use of available social data to investigate how social media interact with democracy and elections. Expanding ethical scholarly access, use, and analysis of a range of social data is critical to understanding the complex ways that social media and other technologies impact political life and processes. COVID-19: The worldwide Covid-19 pandemic has rapidly changed the policy, electoral, and media landscapes related to the 2020 US elections. This grant opportunity's primary emphasis is related to social media and the 2020 elections, as described below; however applications that investigate the impact of the coronavirus pandemic as it intersects with the core themes outlined above are particularly encouraged. For example, explorations of policy debates, news, or disinformation circulated via social media on topics relevant to the 2020 US elections and amplified by circumstances related to Covid-19--such as vote-by-mail debates, health care policy, Covid-19 disinformation campaigns related to the election, and so on--are welcome.

The Global Fund to Fight AIDS, Tuberculosis and Malaria: COVID-19 Response Mechanism
Deadline: by May 31, 2020 or as soon as possible thereafter.
The COVID-19 Response Mechanism supports countries to respond to COVID-19, mitigate the impact on programs to fight HIV, TB and malaria, and initiate urgent improvements in health and community systems. With an initial allocation of $500 million, the COVID-19 Response Mechanism leverages the
principle of country ownership and allows countries to request funding for control and containment, including laboratory networks, supply chains, and community-led response. Eligible applicants include those countries that directly receive Global Fund financing. All funding requests must be coordinated and submitted by the Country Coordinating Mechanism.

data.org/Mastercard/Rockefeller Foundation: Inclusive Growth and Recovery Challenge
Deadline: July 17, 2020
This challenge is an open call for breakthrough ideas that harness the power of data science to help people and communities thrive, especially in the wake of COVID-19’s economic impact. Areas of interest include, but are not limited to: jobs of tomorrow - leave no worker behind; access to capital - leave no entrepreneur behind; and cities and towns - leave no place behind.

Deadline: July 1, 2020
The Foundation has rapid-response research funds available to commission: 1) issue briefs/commentaries or papers/research reviews and; 2) small studies to explore the impact of the coronavirus pandemic on nutrition and diet quality, food security, and related health consequences for children and families. This funding opportunity is focused on USDA Federal Nutrition Assistance Programs serving children and families. The goal is to inform decision-making regarding innovative policies and/or programs during and after the COVID-19 pandemic.

Gordon and Betty Moore Foundation: COViD Decision Modeling Grants
Deadline: June 30, 2020
The COViD Decision Modeling Initiative (CDMI) will support the development of decision models to inform the urgent needs of decision makers responding to the Covid-19 pandemic. To optimize success of decision modeling projects funded for rapid impact, the research team will coordinate efforts from their institutions along with the SMDM COVID-19 Modeling Special Committee to provide connectivity between decision makers and decision modelers and disseminate the combined CDMI results to the public at large. Johns Hopkins University will administer 6-10 agreements to recipients for decision modeling projects with anticipated impact within 4-6 months from start date.

Deutsche Forschungsgemeinschaft (DFG): Call for Multidisciplinary Research into Epidemics and Pandemics in Response to the Outbreak of SARS-CoV-2
Deadline: July 1, 2020
Funding is available for projects addressing the prevention, early detection, containment, and investigation of the causes, impacts, and management of epidemics and pandemics, taking the example of SARS-CoV-2 and other microorganisms and viruses that are pathogenic to humans.

Deadline: Rolling
For time-sensitive research or additions to research projects that study or support the COVID-19 response. This funding window could support projects that:
- Generate new data to directly inform the COVID-19 response of committed partners
- Evaluate interventions that are expected to improve COVID-19 response or recovery
- Add a module to an existing survey in order to track COVID-19 exposure or response
- Add a treatment arm that may support communities’ resiliency in response to COVID-19
• Anonymize, curate, and share already-collected data quickly so that it can be used for decision-making by the humanitarian community
• Conduct a “downstream survey” that follows up on a sample that participated in an already-completed randomized trial in order to identify whether the intervention studied has an impact on the communities’ response to COVID-19

Successful applicants will have a research team or staff that has the necessary experience to study the emergency response. As a result, interdisciplinary teams are encouraged.

**Mercatus Center: COVID-19 Response: A Call for Ideas**
**Deadline: Rolling**
The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic, specifically, in the topics of restarting and reopening, institutional challenges, health and science policy, economic and regulatory policy, and monetary policy.

**Engineering and Physical Sciences Research Council (EPSRC) - United Kingdom**
**Deadline: September 30, 2020**
The Engineering and Physical Sciences Research Council, through the UK-RAS Network and in collaboration with Imperial College London, Wellcome, KUKA and Intuitive Surgical, invites submissions for its medical robotics for contagious diseases challenge. This seeks innovative ideas that could aid in the response to the current COVID-19 pandemic and future global pandemics. The COVID-19 pandemic offers a unique opportunity to galvanize medical robot technologies, as they play an increasingly major role in combating contagious diseases.

**Biogen Foundation: COVID-19 Relief Effort**
**Deadline: Unspecified (accepting applications)**
The Biogen Foundation has committed $10M to aid in COVID-19 relief efforts around the world. At this time, the Biogen Foundation’s COVID-19 relief efforts are focused on the following categories: Expanding and ensuring access to testing; Easing the burden on healthcare systems and healthcare workers; Providing food and necessities for our most vulnerable populations.

**COVID-19 Early Treatment Fund (CETF) and Rockefeller Philanthropy Advisors**
**Deadline: Not announced**
This program funds initiatives that focus on treating outpatients to prevent hospitalization. CETF is narrowly focused on ensuring that outpatient trials for four drugs are successful (Peginterferon lambda, Favipiravir, Camostate mesylate, and Remdesivir). That means we’ll provide funding, help improve study protocols, find ways to manufacture drugs in short supply and do whatever it takes to move these medicines forward.

**New: Draper Richards Kaplan: Coronavirus Urgent Response Initiative**
**Deadline: Not specified**
This initiative supports ideas that are tackling the most acute and time-critical social problems caused by the Covid-19 pandemic right now. DRK wants to help jumpstart projects that can realistically deploy within 30 days.
Coalition for Epidemic Preparedness Innovation (CEPI): Achieving an unprecedented acceleration of vaccine development and global manufacturing capacity to prevent COVID-19
Deadline: rolling until at least June 30, 2020
This call for proposals seeks to accelerate the development of safe and effective vaccines by organizations who can rapidly deliver at scale and to ensure that the supply of vaccine doses is made available to meet the public health need on a worldwide basis during the pandemic.

Ferring COVID-19 Investigational Grants in Reproductive Medicine and Maternal Health
Deadline: October 31, 2020
Ferring is interested in funding exploratory, basic, and clinical research grants to collect data and expand knowledge about the effects of SARS-CoV-2 on reproduction, pregnancy, and fetal/neonatal health. The Ferring COVID-19 Investigational Grants in Reproductive Medicine and Maternal Health (RMMH) are designed to provide funding to gather data related to IVF programs during the COVID-19 pandemic including but not limited to: Follow-up data on infected pregnant patients at different gestational stages, including spontaneous pregnancies; Data on the outcome of ongoing fertility care; Data on gametes/embryos, fresh or frozen, from patients exposed to SARS-CoV-2; and Other information related to fertility outcomes.

American Heart Association: Rapid Response Grant and its Cardiovascular Impact
Deadline: April 06, 2021
This grant invites cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19. Because of the urgency of this issue, innovative, highly impactful short-term proposals (9-12 months), which can show progress within the period of this award, are sought.

Robert Wood Johnson: Pioneering Ideas: Exploring the Future to Build a Culture of Health
Deadline: Continuous
This award seeks ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. While this call for proposals is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, we recognize the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.

Amgen Foundation: COVID-19 Relief Support
Deadline: none
The Amgen Foundation is dedicated to combating this pandemic by working across several fronts to apply their unique strengths in genetics, immunology, and antibody engineering to prevent and treat COVID-19. The Foundation’s COVID-19 Relief Support program is dedicated to supporting patients and communities in the fight against COVID-19. Support is provided in the U.S., including Puerto Rico.

Merck KGaA: Research Grant for Pandemic Preparedness
Deadline: Rolling
This grant seeks proposals that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.
Patient-Centered Outcomes Research Institute: Enhancements to existing Research Projects and Engagement Awards
Deadline: Rolling
PCORI is requesting enhancements to existing Research Projects and Engagement Awards that can be initiated quickly to influence the outcome of the current pandemic and that have some relationship to the original award, using existing teams that are currently funded: COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects; COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards

Fast Grants: Fast Funding for COVID-19 Science
Deadline: Not announced
These grants are for scientists at an academic institution currently working on a COVID-19 related project and in need of funding. Fast Grants are $10k to $500k and decisions are made in under 48 hours.

Mozilla: COVID-19 Solutions Fund
Deadline: Rolling
The fund will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related

California Institute for Regenerative Medicine (CIRM)
Deadline: Open on a bi-monthly basis.
The CIRM has allocated $5 million in funding for peer-reviewed regenerative medicine and stem cell research that could quickly advance treatments for COVID-19. Support is provided for promising discovery, preclinical, and clinical trial stage projects.

IBM: Call for Code Global Challenge
Deadline: July 31, 2020
The Call for Code Global Challenge, an initiative of IBM, asks the world’s developers to build solutions for COVID-19 and climate change. Interests include crisis communication, remote education, and community cooperation.

Nellie Mae Education Foundation: Racism is a Virus Too
Deadline: Rolling basis until resources are exhausted
The Nellie Mae Education Foundation created a rapid response fund to respond to the hate crimes and bias against Asian American communities in New England resulting from COVID-19.

Omidyar Network India: Rapid Response Funding for COVID-19
Deadline: Not announced
The Omidyar Network India has announced a rapid response window to fund proposals that support the lower 60% of India’s income distribution in managing and mitigating the challenges that come with Covid-19. Support is provided for initiatives that strengthen containment, detection and treatment, support crisis management capabilities, and enhance resilience and recovery in the wake of Covid-19.

Open Road Alliance
Deadline: Not announced
The Open Road Alliance is offering charitable grants to organizations responding directly to COVID-19, with priority given to organizations and activities that have a clear and direct role in ‘flattening the curve’ and thus limiting, shortening, or minimizing the economic and social, as well as health effects of the pandemic. Loans are also available to organizations affected by COVID-19, including those with lost event revenue, those delivering vital community services, and social enterprises.

Amazon Web Services (AWS): Diagnostic Development Initiative  
**Deadline:** June 30, 2020  
This Initiative provides support for innovation in rapid and accurate patient testing for 2019 novel coronavirus (COVID-19), and other diagnostic solutions to mitigate future outbreaks.

Enhancing Learning and Research for Humanitarian Assistance: Research for Health in Humanitarian Crises (R2HC) Programme  
**Deadline:** July 16, 2020  
This program aims to improve health outcomes by strengthening the evidence base for public health interventions in humanitarian crises.

Bill & Melinda Gates Foundation, Wellcome and Mastercard: COVID-19 Therapeutics Accelerator  
**Deadline:** varies  
This initiative speeds development and access to therapies for COVID-19 by coordinate R&D efforts and removing barriers to drug development and scale-up to address the epidemic.

Massachusetts Institute of Technology Solve: Health Security and Pandemics Challenge  
**Deadline:** June 18, 2020  
MIT Solve is seeking tech innovations that can slow and track the spread of an emerging outbreak, for example by improving individual hygiene, developing low-cost rapid diagnostics, analyzing data that informs decision making, and providing tools that support and protect health workers.

Massachusetts Institute of Technology Solve: The Elevate Prize for Health Security  
The Elevate Prize for Health Security will be awarded to one Solver team from the Health Security & Pandemics Challenge. This prize is supported by The Elevate Prize Foundation, which recognizes that there are heroes all over the world who are putting their health and safety at risk to treat those who are infected and to save lives. Now more than ever, it is critical to recognize and uplift those who are elevating humanity. The Solver team that is selected will be named an Elevate Prize Global Hero and will participate in both the MIT Solver program and the Elevate Prize Global Heroes program, receiving a minimum of $300,000 over two years and ongoing support from The Elevate Prize Foundation and MIT Solve.

2. Federal COVID-19 Funding Announcements  

**NEW: Partnership for Maternal, NewBorn & Child Health**  
**Deadline:** June 25, 2020  
Through the WHO, this partnership seeks the services of an institution to support high-quality knowledge products on women’s, children’s and adolescents’ health, including vetting knowledge resources for advocacy and action. The scope of work includes quality assurance and control for PMNCH evidence products, in support of PMNCH’s knowledge translation on WCAH, with a strong focus on COVID-19 and WCAH.
*NEW: NIH: Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (US4 Clinical Trial Optional)
Deadline: July 22, 2020
This Funding Opportunity Announcement (FOA) is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH to develop, validate, improve, and implement serological testing and associated technologies. The purpose of the FOA is to establish Serological Sciences Centers of Excellence with the goal of identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing. These US4 Centers will be part of a Serological Sciences Network (SeroNet). Other components of the Network will include Serological Sciences Research Projects (U01), the FNLCR Serology Laboratory, Serological Capacity Building Centers (CBC) and a Serological Sciences Network Coordinating Center (SSNCC) which will be managed through Frederick National Lab for Cancer Research (FNLCR), a Federally Funded Research and Development Center. It may also include SBIR grants and other grants and contracts related to serology associated with SARS-CoV-2. All components are expected to collaborate across the entire Network, sharing data, results, and reagents. This FOA solicits multi-component US4 Center applications, whereas the companion FOA, RFA-CA-20-039, solicits applications for discrete U01 research projects.

*NEW: NIH: Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional)
Deadline: July 22, 2020
This Funding Opportunity Announcement (FOA) is associated with the COVID-19 Supplement funded through the Paycheck Protection Program and Health Care Enhancement Act (P.L. 116-139) which directs the National Cancer Institute of the NIH to develop, validate, improve, and implement serological testing and associated technologies. The purpose of the FOA is to establish Serological Sciences Research Projects with the goals of: identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; and determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing. These U01 Research Projects will be part of a Serological Sciences Network (SeroNet). Other components of the Network will include Serological Sciences Centers of Excellence (US4), the FNLCR Serology Laboratory, Serological Capacity Building Centers (CBC), and a Serological Sciences Network Coordinating Center (SSNCC), which will be managed through the Frederick National Lab for Cancer Research (FNLCR), a Federally Funded Research and Development Center. It may also include SBIR grants and other grants and contracts related to serology associated with SARS-CoV-2. All components are expected to collaborate across the entire Network, sharing data, results, and reagents. This FOA solicits U01 research project applications, whereas the companion FOA, RFA-CA-20-038, solicits multi-component US4 Centers applications. Successful applicants from both FOAs will become members of the Serological Sciences Network.

*NEW: HUD: Education and Outreach Initiative (COVID-19)
Deadline: July 8, 2020
Congress authorized the Fair Housing Initiatives Program (FHIP) in 1987 under Section 561 of the Community Development Act of 1987 as amended (42 U.S.C. 3616). Program regulations can be found at 24 CFR Part 125, which are incorporated by reference in this Notice. As part of the COVID-19 Supplemental Appropriation for the CARES Act of 2020, Congress appropriated 1 million dollars for FHIP. The purpose of this Notice is to seek applications from eligible entities that will create and disseminate fair housing education and outreach materials in COVID-19 affected areas. During this national emergency, HUD wants to remind housing providers and the public of important federal fair housing laws that protect persons from discrimination, including harassment and intimidation in housing and related services on the basis of race, color, religion, national origin, sex, familial status and disability. HUD is already aware that persons with disabilities, including those who are older and have underlying medical conditions, are vulnerable and at high risk for a severe, life-threatening response to COVID-19. HUD recognizes that these persons may face unique fair housing and civil rights issues in their fair housing related services. Housing providers are required to make reasonable accommodations that may be necessary to deliver housing and services to persons with disabilities affecting major life activities. In addition, HUD wants to prevent discrimination and harassment against people of who, because of racial profiling, are perceived to be associated with this disease. Historically, the number of fair housing complaints increases in the aftermath of a disaster or emergency. Essential to control the number of Fair Housing Act violations during this critical time, is the provision of widespread, highly visible outreach and education activities regarding the Fair Housing Act requirements.

NSF: Environmental Research and Education Advisory Committee Civic Innovation Challenge

Deadline: July 1, 2020
This Challenge is a research and action competition in the Smart and Connected Communities domain designed to build a more cohesive research-to-innovation pipeline and foster a collaborative spirit. Building on the NSF S&CC program and the extensive S&CC ecosystem, CIVIC aims to accelerate the impact of S&CC research, and deepen cooperation and information sharing across sectors and regions. CIVIC will lay a foundation for a broader and more fluid exchange of research interests and civic priorities that will create new instances of collaboration and introduce new areas of technical and social scientific discovery. CIVIC will fund projects that can produce significant community impact within 12 months (following a four-month planning phase) — in contrast to many community-university partnerships that take years to provide tangible benefits to communities — and have the potential for lasting impact beyond the period of the CIVIC award.

United States Patent and Trademark Office, Department of Commerce

Deadline: July 13, 2020
The USPTO will grant qualified requests for prioritized examination without payment of certain fees associated with prioritized examination for applicants that qualify for small or micro entity status. The COVID-19 Prioritized Examination Pilot Program will accept requests for prioritized examination beginning July 13, 2020 until such time as the USPTO has accepted a total of 500 requests. The USPTO may extend the pilot program (with or without modifications) or terminate it depending on the workload and resources needed to administer the program, feedback from the public, and the effectiveness of the program. Patents 4 Partnerships is a new online marketplace for patent owners to list patents and published applications that are available for licensing in fields that address COVID-19. The goal is to better connect in-demand intellectual property with industries interested in scaling the ideas.

Emergency Awards: Research Projects in SARS-CoV-2 Serological Sciences (U01 Clinical Trial Optional) (RFA-CA-20-039)
Deadline: July 22, 2020
The purpose of the FOA is to establish Serological Sciences Research Projects with the goals of: identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; and determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing.

**Emergency Awards: SARS-CoV-2 Serological Sciences Centers of Excellence (U54 Clinical Trial Optional)** (RFA-CA-20-038)
Deadline: July 22, 2020
The purpose of the FOA is to establish Serological Sciences Centers of Excellence with the goal of identifying and advancing research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection; understanding the mechanisms driving the serological, humoral and cellular immune responses; determining host, genetic, and environmental modifiers of the immune response; determining the serological correlates of disease pathogenesis and protection against future infection; defining access, communication, and implementation barriers related to SARS-CoV-2 serological testing.

**HHS: ATSDR’s Partnership to Promote Local Efforts to Reduce Environmental Exposure - COVID-19 Supplement Synopsis 1**
Deadline: June 30, 2020
Potential COVID-19 related work under this supplemental funding opportunity may include providing guidance and community engagement on safe practices for disinfection for home, school and early learning education centers, and assist in COVID-19 response and prevention efforts by conducting environmental assessments, establishing and promoting plans and policies for addressing environmental impacts, and strengthening partnerships among the environmental, epidemiological, and laboratory responses. APPLETREE grantees could also help to prepare for hurricane season and sheltering with COVID-19 mitigations, evacuations due to wildfires while COVID-19 shelter-at-home is in place, and adapt guidance for chemical or radiologic emergencies in light of COVID-19.

**HHS: PEHSU COVID-19 Emergency Response Supplement**
Deadline: June 17, 2020
The Pediatric Environmental Health Specialty Units (PEHSU) are actively engaged in providing guidance on safe disinfectant to combat transmission of COVID19 and promote healthy home and community environments. This initiative will build off of the current work and bring it to scope for targeted implementation nationally. Further, the PEHSU will provide leadership, instructional content, and technical support on guidance for the prevention of infectious disease by addressing personal behaviors, food handling, and household cleaning practices that reduce transmission of COVID19 and other infectious disease. The PEHSU will build and coordinate a consortium of public health partners in developing and tailoring educational content, key messages and guidance materials to meet the needs of the consortium’s target populations. The consortium partners are proposed to be Association of State Public Health Nutritionists, Children’s Environmental Health Network, and the National Environmental Health Association, and the American College of Medical Toxicology. Each Consortium partner will work with defined target populations with specific needs. Each partner will use their skills to deliver the Healthy Environments risk reduction education to meet those specific needs. The PEHSU Regions will provide regional coordination for cross cutting outreach efforts applying social media and use of other communication channels. Additionally, the primary target population for PEHSU will be the health care community and other community-based organizations. Those in this population may include national clinic networks like the Migrant Health Clinics, hospital community medicine programs, health and
wellness programs, and other programs providing community or clinic-level patient education. These may include childbirth educators, community health workers, and youth development organizations who can to educate their clients and communities healthy on environment practices.

**Notice of Special Interest: Competitive and Administrative Supplements for Community Interventions to Address the Consequences of the COVID-19 Pandemic for Health Disparity and Vulnerable Populations (R01 - Clinical Trial Optional) (NOT-MD-20-023)**

**Deadline: Rolling through December 15, 2020**

This Notice encourages investigators to acquire and leverage partnerships with key stakeholders to test community interventions to ameliorate the impact of psychosocial, sociocultural, behavioral, and socioeconomic consequences of COVID-19 on the health of populations known to experience health disparities and other vulnerable populations. Projects may evaluate existing or ongoing community-based programs or policies (i.e., natural experiments) or prospectively test new or adapted interventions. Projects that do not solely target individuals but also address the upstream determinants that influence individual functioning and health outcomes will be strongly encouraged.

**Notice of Special Interest (NOSI): NIDCD is interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders (NOT-DC-20-008)**

**Deadline: October 05, 2020**

NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

**Notice of Intent to Publish a Funding Opportunity Announcement for Digital healthcare interventions to address the secondary health effects related to social, behavioral, and economic impact of COVID-19 (R01 - Clinical Trial Optional) (NOT-MH-20-058)**

This Notice encourages investigators to acquire and leverage partnerships with digital health developers and/or existing well-established digital health delivery platforms, to consider applying for research support that follows a deployment-focused model of services design and testing. Research areas supported under this program include: reach, access, engagement, and effectiveness to screen and treat health conditions at scale not possible through traditional healthcare settings, including for areas and populations where healthcare access may be limited or not utilized. Proposed research should reflect the highest impact, with rigorous methods including sufficient power, and consideration of urgent public health needs in the context of populations eligible for consideration under this effort. This FOA will require focus on health disparate and vulnerable populations.


**Deadline: TBA**

NIMH has already made a significant investment in a data repository to hold human subjects data related to mental illness and related fields. This repository allows data from multiple sources to be aggregated and easily accessed by the research community. However, the data repository is most useful when research laboratories collect data using the same set of data elements. With this Notice, NIMH offers guidance on the use of consensus-derived common data elements (CDEs) pertaining to mental health outcomes that were previously discussed in NOT-MH-15-009 and a set of newly available measures regarding experiences during the COVID-19 public health emergency and exposures to the SARS-CoV-2
virus (the virus that causes COVID-19). The goal of this Notice is to reduce proliferation of one-off survey items and to facilitate data integration, collaboration, and comparisons across data sets.

NIH: Notice of Special Interest (NOSI): Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19) (NOT-AT-20-012)
Deadline: Rolling through August 17, 2020
To rapidly establish scientific evidence and/or elucidate the mechanism of action of natural product–based remedies for SARS-CoV-2 and COVID-19, NCCIH is encouraging the submission of applications for administrative supplements or competitive revisions of active NCCIH grants.

Notice of Special Interest (NOSI): Administrative Supplements to Existing NIH ECHO Cooperative Agreements (Admin Supp - Clinical Trial Not Allowed) for Coronavirus Disease 2019 (COVID-19) – related Research (NOT-OD-20-107)
Extended deadline: June 29, 2020
This NOSI encourages eligible ECHO cohort grantees to apply for this administrative supplement aimed at fostering time-sensitive ECHO-wide Cohort science related to the COVID-19 pandemic. The ECHO Program’s mission is to enhance the health of children for generations to come. Understanding the effects of a broad array of early environmental exposures on child health and development, including issues related to the COVID-19 pandemic, is a priority for the NIH.

NIH: Notice of Change to Eligible Activity Codes for NOT-NS-20-051 "Notice of Special Interest: Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System" (NOT-NS-20-074)
Deadline: varies
The purpose of this notice is to inform interested applicants of a change to the eligible activity codes for NOT-NS-20-051 "Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System". Effective immediately, the RF1 activity code will be added as an eligible activity code to NOT-NS-20-051, for applications submitted to both, PA-18-591 "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) " and PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)".

USAID/Bangladesh and the Private Sector: Partnering to Fight COVID-19 Agency for International Development
Deadline: April 29, 2021
The goal of the USAID Bangladesh and the Private Sector: Partnering to Fight COVID-19 program is to provide a medium through which organizations can work with USAID and the private sector to build Global Development Alliances (GDAs) that will: a) respond to the current outbreak of COVID-19 in Bangladesh; b) address important business interests and objectives; and c) advance USAID’s strategic priorities and objectives.

IARPA: COVID-19 Seedling Research Topics
Deadline: July 7, 2020
IARPA invests in high-risk/high-payoff research programs that have the potential to provide our nation with an overwhelming intelligence advantage. The current COVID-19 pandemic focuses attention on the need for technologies to assist with:
• detection and sensing;
• supply chain management and integrity;
• geo-spatio-temporal monitoring and mapping, with privacy protection;
• information reliability and collaboration tools; and
• modeling, simulation, and predictive analytics.

Deadline: June 30, 2020
The United Nations Development Programme and Hackster.io are joining forces with the world’s brightest technology companies. We are calling on hardware and software developers, product designers, scientists, hackers, makers, and innovators to come together to work for those who will be hardest hit by this pandemic. This challenge has three priority actions: Design replicable, low-cost tools to aid in coronavirus detection; Flatten the curve in communities with preventive solutions; Reduce the disease’s impact on economies of these vulnerable areas.

NIH: Notice of Intent to Publish a Funding Opportunity Announcement for Serological Sciences Centers of Excellence (NOT-CA-20-066)
Deadline: July 20, 2020
The National Cancer Institute intends to publish a Funding Opportunity Announcement as a Request for Applications to solicit applications to establish Serological Sciences Centers of Excellence of collaborating investigators and an RFA for research projects. Specifically, both the Centers and the projects will identify and advance research opportunities to characterize the immune responses elicited by SARS-CoV-2 viral infection, especially as it relates to cancer patients.

NIH: Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01)
Deadline: 06-16-2020
AHRQ is interested in funding critical research focused on evaluating topics such as effects on quality, safety, and value of health system response to COVID-19; the role of primary care practices and professionals during the COVID-19 epidemic; understanding how the response to COVID-19 affected socially vulnerable populations and people with multiple chronic conditions; and digital healthcare including innovations and challenges encountered in the rapid expansion of telehealth response to COVID-19.

Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-051)
Deadline: June 16, 2020
In order to rapidly improve our understanding and available control measures for SARS-CoV-2 and COVID-19, NIAID is encouraging the submission of applications to address the following research areas of interest:
• Studies to understand critical aspects of viral infection, replication, pathogenesis, and transmission;
• Studies on the evolution and emergence of SARS-CoV-2 viruses including the identification of factors that affect viral host-range and virulence;
• Development of sensitive, specific, and rapid clinical diagnostic tests for SARS-CoV-2;
• Development of SARS-COV-2 therapeutic candidates, especially broad-spectrum therapeutics against multiple coronavirus strains;
Identification and evaluation of the innate, cellular and humoral immune responses to SARS-CoV-2 infection, including, but not limited to: cross-reactive antibodies from individuals exposed to SARS-CoV-2 and other coronaviruses; viral epitopes critical for T cell activation or antibody binding and neutralization; immune-mediated pathology or host factors that might predispose to severe infection; and studies to examine duration of protection or the potential for reinfection; and

Development of SARS-CoV-2 vaccine candidates, including approaches for pan-coronavirus protection, that include emerging antigen design strategies, novel platforms or delivery approaches, adjuvants, or assessing cross-neutralization potential of SARS-CoV vaccine candidates.

Notice of Early Expiration of “Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Update NOT-AI-20-031 Deadline: varies

This NOSI has a narrower research focus and directs interested applicants to the following funding opportunity announcements:

- **PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)**
- **PA-19-272 PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)**
- **PA-19-270 PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)**

**NIH: NIBIB: Rapid Acceleration of Diagnostics (RADx) Initiative for COVID-19**
Deadline: rolling
NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of product development including commercialization and product distribution. Project proposals accepted through online RADx portal.

**NIH: Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)**
Deadline: June 8, 2020 and March 17, 2021
This funding opportunity announcement (FOA) solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOA’s companion for basic experimental studies with humans.

**DOS: U.S. Mission to India - COVID-19 Small Grants Program**
Deadline: September 30, 2020
This funding opportunity seeks to support effective coalitions that will bolster and leverage U.S.-India collaboration across a range of fields to fight COVID-19, in India and globally. Potential grantees should be able to implement a small-grants program to promote innovation in addressing COVID-19, encourage partnerships between U.S. and Indian institutions and organizations in combating COVID-19, and facilitate joint action that makes a difference against the disease. The grant will provide resources for a grantee to manage and administer small grants to stakeholders from government organizations, non-profits, think tanks, academic institutions, incubators and accelerators, in close coordination with the U.S. Mission to India. The grantee will be required to solicit proposals that contribute to and/or build upon initiatives that
counter the impact of COVID-19 on Indian society, U.S.-India cooperation, and wider communities across the Indo-Pacific region.

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System (NOT-N5-20-051)
Deadline: May 1, 2020-April 15, 2021
NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

HHS: Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed) (PAR-20-177)
Deadline: April 30, 2021
This opportunity provides an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) (PAR-20-178)
Deadline: Rolling
This opportunity provides an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis (NOT-CA-20-054)
Deadline: Not announced
The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship.

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials
Deadline: October 6, 2020
NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19. It is strongly recommended that the parent activity code be one of the following: P01, R01, R33, R41, R42, R43, R44, U01, U24, U54, UH3, or UM1. Topics of specific interest to the NHLBI include the safety and efficacy of interventions for primary prevention and/or treatment of COVID-19, associated clinical phenotypes, and surrogate outcomes, relevant to heart, lung, and blood (HLB) diseases.
**NOSI: Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)**

*Deadline: June 19, 2020*

OSC seeks new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. *Topics:* Any relevant area of innovative research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics.

**NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System**

*Deadline: April 14, 2021*

This NOSI highlights the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

**UK Ministry of Defense/Defense and Security Accelerator: Point of Care Diagnostics at the Front Line**

*Deadline: September 26, 2020*

This call supports diagnostics technologies that provide information to enable clinicians to earlier diagnose and ultimately treat individuals exposed to chemical and biological hazards. Proposals should address technologies that would enable the diagnosis of individuals exposed to a wide variety of agents, regardless of starting technology readiness level, up to TRL 6. These technologies can be targeted at the agents themselves or at host biomarkers that change as a result of exposure.

**National Institute of Biomedical Imaging and Bioengineering (NIBIB): Rapid Acceleration of Diagnostics (RADx)**

*Deadline: Rolling*

This call supports novel solutions that build the U.S. capacity for SARS-CoV-2 testing up to 100-fold above what is achievable with standard approaches. *Topics:* SARS-CoV-2 diagnostic testing technologies in two stages: Early stage: transformative innovations based on novel testing strategies that have potential for major scale up; Advanced stage: modification and optimization of existing SARS-CoV-2 testing approaches, including clinical laboratory tests, that can dramatically increase testing capacity.


*Deadline: varies May 04, 2020 through November 11, 2020*

NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients.

**Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)**

*Deadline: varies*

NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address the following research areas of interest:
Notice of Eligibility Change for NIDCD Urgent Competitive Revisions and Administrative Supplements for Research on COVID-19
Deadline: n/a
This NOSI revises the language regarding the activity codes of currently funded NIDCD grants that are eligible to apply to NOT-DC-20-004, Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19). Current Language: Only R01 and U01 activity codes of currently funded NIDCD grants are eligible to apply to this NOSI. The funding instrument, or activity code, will be the same as the parent grant; Revised Language: Only R01, U01, R42, and R44 activity codes of currently funded NIDCD grants are eligible to apply to this NOSI. The funding instrument, or activity code, will be the same as the parent grant.

Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA
Deadline: various through April 16, 2021
This NOSI encourages applications to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (NOT-MD-20-019)
Deadline: Rolling through May 2, 2021
The National Institute on Minority Health and Health Disparities seeks research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-017)
Deadline: Rolling - May 15, 2020- January 26, 2022
For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-016)
Deadline: Rolling - May 15, 2020 through January 25, 2022
For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus (NOT-MH-20-047)
Deadline: Rolling - March 27, 2020-April 16, 2021
For research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.

Notice of Special Interest (NOSI): National Cancer Institute Announcement regarding Availability of Competitive Revision SBIR/STTR Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-CA-20-043)
Deadline: Rolling - April 14, 2020-June 26, 2020
This NOSI encourage applications from small businesses with NCI-funded active NCI SBIR/STTR awards that have a strong potential to be adapted/repurposed for use as a prophylactic, therapeutic or diagnostic tool for SARS-CoV-2 (COVID-19) in cancer patients, cancer survivors, and in the general population.

Deadline: Rolling - May 01, 2020-May 04, 2021
For research to understand the impact of environmental exposures on (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus. NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) (NOT-AI-20-030)
Deadline: varies
NIAID and NIGMS are offering Competitive Revisions to active grants addressing research objectives focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.

Notice of Special Interest: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed) (NOT-ES-20-014)
Deadline: varies
NIEHS WTP grantees are re-programming existing extramural funds to provide Coronavirus preparedness training to their worker populations. The newly proposed training under this announcement would be utilized to award supplemental funding to expand these ongoing Coronavirus response training efforts.

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-20-012)
Deadline: October 17, 2020
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial. The hypothesis for proposed studies must be developed using innovative processes.
to identify the therapeutic/indication pair. NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-HG-20-030)
Deadline: varies
This NOSI encourages the submission of applications for Competitive Revisions to support genomic research on SARS-CoV-2 and COVID-19 disease. Of particular interest are genomic studies utilizing generalized approaches that take advantage of human research or model systems to study the consequences of SARS-CoV-2 infection. Supported research is expected to guide and inform future efforts to diagnose, prevent, mitigate, or treat this viral infection.

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
Deadline: varies
NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address the following NIA division research interests: Aging Biology; Neuroscience; Geriatrics and Clinical Gerontology; and Behavioral and Social Research.

HHS: Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)
Deadline: June 16, 2020
The U34 award will support clinical trial planning. This includes collection of feasibility data and complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use. The clinical trial that is being planned must aim to repurpose existing drugs or biologics (therapeutics) that have already completed at least a Phase I trial for a different indication by the time a clinical trial planning award is made. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair.

Deadline: varies
This NOSI highlights the urgent need for research on the 2019 novel Coronavirus, particularly in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
Deadline: varies
There is an urgent public health need to better understand SARS-CoV-2, particularly to improve the predictive quality of existing models of spread, diagnostics for measurement of transmission, susceptibility and recovery, and development of therapeutic interventions. NIGMS will accept the
submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:

- Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
- Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
- Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only)

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047)

Deadline: varies

NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional); and PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

Notice of Special Interest (NOSI) Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need (NOT-R-20-111)

Deadline: varies

National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel Coronavirus (COVID-19). NCATS is particularly interested in projects focusing on the use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines. NCATS is soliciting applications for Administrative Supplements to UL1, U01, and R21 awards (through PA-18-591), Collaborative Innovation Awards to U01 and R21 awards (through PAR-19-099 and PAR-19-100, respectively), and Competitive Revisions for UL1 awards for each of the non-administrative supplement awards (through PAR-19-337).

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)

NIGMS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on SARS-CoV-2 and Coronavirus Disease 2019 (COVID-19).

HHS: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)

Deadline: September 25, 2020

This FOA solicits competitive revision applications to support the demonstration, and/or dissemination, and/or implementation of highly innovative and impactful translational science projects that address the goals of the CTSA Program that are beyond the original scope of the approved project. Projects will be considered for an increase in support for an expansion of the parent project’s approved scope.

HHS: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)
Deadline: July 11, 2019
Thus opportunity supports investigators from three or more CTSA Program hub institutions to either: 1) form new collaborations, or to 2) significantly expand the scientific scope of existing collaborations, or to 3) engage new collaborators in pre-existing collaborations to solve a translational science problem no one hub can solve alone, or disseminate a solution to a translational science problem developed at one hub to other hubs, in so doing testing its robustness to different hub environments and structures and adapting it for further dissemination within outside the CTSA Program consortium if appropriate.

HHS: Partnerships for Countermeasures against Select Pathogens (R01 Clinical Trials Not Allowed)
Deadline: June 20, 2020
This opportunity solicits research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics, vaccines and related countermeasures against select NIAID Emerging Infectious Diseases/Pathogens.

NIH - NIAID and NIGMS: Notice of Special Interest regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Deadline: Applications accepted on a rolling basis from February 6, 2020 through February 6, 2021
NIAID and NIGMS highlight the urgent need for research on the 2019 novel Coronavirus: NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV; and NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.

NIH – NHLBI: Notice of Special Interest: Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019
Deadline: October 6, 2020
NHLBI is issuing this Notice of Special Interest to highlight the urgent need for research on Coronavirus Disease 2019 and on biological effects of its causative agent, the severe acute respiratory syndrome. Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

NIH: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
Deadline: varies
NIH is taking several approaches to support new research in response to severe acute respiratory syndrome coronavirus 2 and coronavirus disease 2019. If you are a grantee currently supported by active NIH funding, you may be eligible to apply for an administrative supplement to support SARS-CoV-2/COVID-2019 research.

NIH: Urgent Award Mechanism, Competitive Revisions to Existing NIH Grants
Deadline: varies
The National Institutes of Health (NIH) hereby notify Principal Investigators holding specific types of NIH research grants, listed in the full Funding Opportunity Announcement (FOA) that funds may be available for competitive revisions to meet immediate needs to help address a specific public health crisis in a timely manner, but that were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. Applications for Urgent Competitive Revisions will be routed directly to the NIH awarding component listed on the NoA of the most recent parent
award. Only applications submitted in response to an Urgent Guide Notice published by an IC will be allowed to apply to this FOA.

NIH – NIDA: Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Deadline: Applications will be accepted on a rolling basis through March 31, 2021
NIDA is issuing this notice to highlight the urgent need for research on the 2019 Novel Coronavirus. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

NSF: Dear Colleague Letter 20-052 re Corona Virus Proposals
Deadline: varies
NSF is accepting proposals to model, track, inform, educate, and prevent the spread of Coronavirus through its existing funding opportunities. NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Visit NSF, Dear Colleague 20-053 for Coronavirus proposal FAQs and conditions and process for proposal deadline extension.

NSF-Office of Advanced Cyberinfrastructure (OAC), Dear Colleague Letter 20-055
Deadline: varies
OAC is inviting Rapid Response Research (RAPID) funding mechanism proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

HHS: Development of Medical Products for Novel Coronavirus: Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
Deadline: October 31, 2020
This amendment solicits proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals.

HHS/CDC: Prototype Development to Combat Novel Coronavirus Disease COVID-19
Deadline: April 30, 2020
The Government seeks to rapidly accelerate the inquiry, testing, and fielding of new 21st century capabilities, employing novel technologies and approaches to the detection of exposure, prevention, containment and treatment of COVID-19 and future emerging threats.

DOE: Invitation for COVID-19 Scientific Questions (DOE Resources)
Deadline: Ongoing
The Department encourages scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure. Please send research questions that the scientific community may address with DOE resources by email to SC.DCL@science.doe.gov.

Previously Announced NIH Limited Submission Opportunities
Limited Submission - NIH Director’s Emergency Early Independence Awards (DPI Clinical Trial Optional) (RFA-RM-20-021)
Limited Submission - NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional) (RFA-RM-20-020)
Sponsor deadline: September 4, 2020

3. COVID-19 related research news and policy updates

A few of the provisions in the third COVID-19 relief/response package that might be of particular interest to researchers is below. To read more, please download a section-by-section summary and the legislative text.

- NIST - $6 million to provide continuity of operations and to conduct research and measurement science to support the testing and treatment of coronavirus. Page 622 of the legislative text.
- NSF - $75 million to support research at molecular, cellular, physiological and ecological levels to better understand coronavirus genetics, modes of action, transmission, virulence, and population dynamics. It is expected that many of these funds will be available through the Rapid Response Research funding mechanism. Read Dear Colleague Letter here. Page 629.
- DOE Office of Science - $99.5 million for costs related to equipment, personnel, and operations to support research on the coronavirus, including support to provide access to user facilities. Page 654.
- EPA S&T - $1.5 million to support research efforts regarding coronavirus – and specifically, research on methods to reduce risks from environmental transmission via contaminated surfaces. Page 713.
- CDC - $4.3 billion to support federal, state, and local public health agencies to prevent, prepare for and respond to the coronavirus. Included in that amount is $500 million for global disease detection and emergency response, $500 million for public health data surveillance and analytics infrastructure modernization, and $300 million for the Infectious Diseases Rapid Response Reserve Fund, which supports immediate response activities during outbreaks. Page 728.
- NIH - The bill includes $945 million to support research and expand on prior research plans, including developing an improved understanding of the prevalence of COVID-19, its transmission and the natural history of infection, and novel approaches to diagnosing the disease and past infection, and developing countermeasures for the prevention and treatment of its various stages. Of this total, $103 million is allocated for NHLBI, $706 million NIAID, $60 million NIBIB, $36 million NCATS, $30 million OD, and $10 million for National Library of Medicine. When combined with the first supplemental, Congress has provided $1.78 billion for NIH research on COVID 19. Page 730.
- BARDA (Biomedical Advanced Research and Development Authority) - At least $3.5 billion to advance construction, manufacturing, and purchase of vaccines and therapeutics to the American people.
- NASA - $60 million to support NASA with resources for operational adjustments associated with mission delays caused by NASA center closures related to coronavirus. Page 628. Also, the package includes a number of health-related authorizations, including the HRSA health professionals and nursing workforce development programs.

4. Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19

NIH

- Considerations for New and Ongoing Human Subjects Research During the COVID-19 Public Health Emergency under Human Subjects
- Coronavirus Update: Guidance for Peer Reviewers
• OHRP Guidance on COVID-19 under Human Subjects and Clinical Trials
• NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-HL-20-759)
• notice on Guidance for Cost-Related Flexibilities Available to Support of Competitive Research (SCORE) Award Recipients Affected by COVID-19
• Virtual NIH Activities for Trainees Outside the NIH
• Animal Welfare: COVID-19 Pandemic Contingency Planning for Animal Care and Use Programs
• Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding. The page now includes a link to page update history so you can easily see what’s new.
• New guidance of flexibilities for awardee, students and conference funding during COVID-19 period
• FAQs including new section on Training, Fellowship and Career Development Awards
• An FAQ to address questions regarding proposal submission and award management
• A lenient late-application policy for those who are unable to meet application deadlines due to the COVID-19 emergency
• NIH grant recipients may extend the final budget period of the approved project on active grants one time for up to 12 months without requesting prior approval from NIH

Other Federal Guidance
• USAMRAA’s Supplemental Guidance on Administrative Flexibilities for Grants and Cooperative Agreements in Response to COVID-19 Pandemic
• Frequently Asked Questions (FAQs) published by The Department of Defense (DoD)

5. Free access and free services for researchers related to COVID-19

• NIH VideoCast is a free National Library of Medicine webinar for researchers to learn how to share, discover, and cite COVID-19 data and code in generalist repositories.
• NIH Resource to Analyze (COVID-19) Literature: The COVID Portfolio Tool
  NIH Office of Portfolio Analysis (OPA) has built a comprehensive listing of (COVID-19) publications, available to the public. The portfolio is updated daily and draws from PubMed resources for citations and abstracts of published biomedical literature.
• The COVID-19 High Performance Computing (HPC) Consortium is a unique private-public effort spearheaded by the White House Office of Science and Technology Policy, the U.S. Department of Energy and IBM to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines.
• COVID-19 Collaboration Platform: This platform is a home for RCT protocols that are available for collaboration.
• CD2H COVID Case Report Forms and Phenotyping Standards website
• The Center for Leading Innovation and Collaboration COVID-19 page
• The American Heart Association is working to ensure optimal care for patients with cardiovascular disease who contract coronavirus (COVID-19). Patients with underlying cardiovascular diseases appear to have an increased risk for adverse outcomes with COVID-19. Here are helpful resources for health systems, clinics, care providers, patients and the public.
- National Library of Medicine, through its GenBank® sequence database, is providing the biomedical community free and easy access to genome sequences from the novel coronavirus associated with the recent outbreak of pneumonia in Wuhan, China. The outbreak was declared a global health emergency on January 30, 2020 and GenBank® continues to rapidly release data associated with this outbreak as it comes in and welcomes sequence data submissions as well.

- Internal: FAS Research Computing has offered to provide enhanced support to Harvard Chan School research related to COVID-19. Examples of support include help with workflow automation to improve efficiency for COVID-19 data analysis, and prioritized assistance for virtual machine requests for hosting a COVID-19 analytic tools website. For more information, please contact the FASRC team via email or attend one of their virtual office hours which are held weekly on Wednesdays from 12 PM to 3 PM.

- Open Research Dataset (CORD-19) is a resource of over 45,000 scholarly articles, including over 33,000 with full text, about COVID-19, SARS-CoV-2, and related coronaviruses.

- IBM has resources to share — like supercomputing power, virus tracking and an AI assistant to answer citizens’ questions.

- LitCovid is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus.

- The National Institute of Allergy and Infectious Diseases (NIAID) has made 2019 SARS-CoV-2 and other Coronavirus strains and reagents available through its BEI Resources Repository.

- The American Journal Experts are offering free language editing and translation services for articles related to coronavirus disease 2019

- Sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak, with NIH as a signatory to the statement Wellcome Trust news, January 31, 2020

- The BMJ: Coronavirus

- Chongqing VIP Information, a Chinese journal database

- Elsevier: Novel coronavirus information center

- The Lancet: COVID-19 resource centre

- New England Journal of Medicine: free Journal content on coronavirus

- Royal Society of Tropical Medicine and Hygiene: Coronavirus free collection

- Springer Nature, the publisher of Nature: Novel coronavirus (SARS-CoV-2 and COVID-19)

- Wiley Online Library: COVID-19 resources and news

- WHO: COVID-19 Course Series - free online courses from OpenWHO

6. COVID-19 news by Chan faculty

- Find the latest COVID news by Chan faculty here.